Wegovy Cost: Complete Guide to Pricing and Payment Options

Wegovy List Price: Understanding What You're Quoted

NovoCare's current Wegovy page defines list price as the manufacturer's original price before discounts or rebates and displays $1,349.02 per package for the Wegovy pill, pen and HD pen. A package is not automatically one injection or one pen. For injection self-pay terms, NovoCare defines a monthly supply as one box of four single-dose pens; tablet terms use a bottle of 30 tablets.

List price is a reference point, not a prediction of what a patient or plan pays. The presentation, dose, quantity, deductible, negotiated price, pharmacy and program eligibility all matter. Keep oral and injectable presentations separate when comparing quotes.

Insurance Coverage: Does Your Plan Cover Wegovy?

Commercial plans decide whether and how Wegovy is covered. Check the exact formulary entry, indication, prior-authorization criteria, deductible and coinsurance rather than relying on a general BMI rule or a named insurer. A commercial savings card may reduce an eligible patient's responsibility, but it does not make a plan cover Wegovy.

Ask the plan or pharmacy: Is the prescribed Wegovy presentation covered? What quantity is authorized? Is prior authorization or renewal documentation required? What will count toward the deductible and out-of-pocket limit? Those answers are more useful than a generic monthly estimate.

Expected Copays: What You'll Pay With Insurance

Some plans use a fixed copay; others use coinsurance based on a negotiated price. For illustration only, if a plan negotiated a $1,000 price and charged 20% coinsurance, the arithmetic would be $200. That example is not a Wegovy quote and does not account for a deductible or out-of-pocket maximum.

Before starting, ask for a written or portal estimate for the exact dose and quantity. Also ask whether a manufacturer offer can be used with the plan. Government coverage has separate restrictions from commercial savings programs.

Novo Nordisk Savings Program: Reducing Your Copay

NovoCare presents separate commercial-insurance and self-pay pathways. For eligible commercially insured patients with coverage for Wegovy, the current offer says “as little as $25” and limits savings to a maximum $100 per monthly fill (28 days for injection or 30 tablets for oral); it is not a guaranteed $25 cost for every covered patient. The commercial offer excludes government prescription coverage. Read the current offer terms for eligibility and expiry conditions.

Government-insured people may use self-pay outside insurance coverage through the separate pathway, but that purchase does not receive insurance reimbursement or credit a deductible or Part D TrOOP. For eligible new self-pay patients with no Wegovy offer in the prior 365 days, the current display lists $199 for each of the first two 28-day fills of 0.25 mg or 0.5 mg injection through December 31, 2026. The supply is one box of four pens. After those fills, its standard self-pay examples are $349 per 28-day fill for 0.25, 0.5, 1, 1.7 or 2.4 mg injections and $399 for HD 7.2 mg. Tablet prices are separate: $149 for 1.5 mg, $199 for 4 mg, and $299 for 9 mg or 25 mg per 30-tablet bottle.

Because Wegovy is not listed in NovoCare's current patient-assistance product list, a general patient-assistance page is not a free-Wegovy offer.

GoodRx and Discount Pharmacy Cards

GoodRx can be useful for a cash comparison, but search the exact branded Wegovy presentation, dose, quantity and pharmacy location. The current Wegovy price page shows examples such as four-pen cartons and separate tablet bottles; it warns that default quantities vary and retail prices are averages, not a location-specific pharmacy quote.

• Compare the exact Wegovy dose and package, not a generic “semaglutide” result.
• Ask the pharmacy to confirm the cash price before presenting the coupon.
• Compare the quote with insurance, the applicable Novo offer and other discount cards one at a time.
• Remember that GoodRx discount restrictions apply; a discount cannot be combined with insurance or Medicare for the same fill.

GoodRx Gold is a separate membership, not insurance and not the medication price. Its current terms describe the membership limits; savings depend on the prescription, participating pharmacy and location. Use the current lookup instructions rather than a generic savings range.

Compounded Semaglutide: Risks and Considerations

Compounded semaglutide is not the FDA-approved Wegovy product. The FDA's GLP-1 information explains that compounded products are not FDA-approved before marketing; that does not mean there is no oversight. A patient-specific compound must be evaluated under the applicable federal and state framework, and a pharmacy's product is not automatically the same formulation, strength, sterility, labeling or clinical evidence as Wegovy.

The FDA compounding Q&A and current copy-rule clarification are more useful than a blanket “legal” or “illegal” label. Shortage status, prescription-specific need, significant-difference documentation, pharmacy oversight and product availability can change. Cost alone does not establish equivalence or make a compound the right alternative. Our compounded semaglutide guide provides more context.

Medicare and Medicaid Coverage (Updated 2026)

Medicare coverage is indication- and pathway-specific; it is not automatic coverage for every adult with obesity. The current CMS Medicare GLP-1 Bridge demonstration runs from July 1, 2026 through December 31, 2027. Its eligibility summary starts with adults 18 or older enrolled in a qualifying Part D plan and includes BMI 35 or higher, or BMI 30 or higher with specified HFpEF, uncontrolled hypertension or CKD stage 3a or higher, or BMI 27 or higher with prediabetes, prior myocardial infarction or stroke, or symptomatic peripheral artery disease. A prescriber must certify participation in a lifestyle program, and prior authorization may apply. Eligible participants pay a $50 monthly copay outside the ordinary Part D payment flow; CMS says it is not subject to the Part D deductible, does not credit Part D TrOOP and does not receive the low-income subsidy.

CMS materials route people already using a Part D GLP-1 pathway, or seeking treatment for type 2 diabetes, moderate-to-severe obstructive sleep apnea or fatty liver disease, to ordinary Part D rules instead of the Bridge. That routing does not replace the product label or establish coverage for every condition. The Medicare weight-loss coverage page and the member's plan should control the current answer. Medicaid coverage remains state-, indication- and date-dependent; do not infer a national copay or named-state list from this guide.

Cost Comparison: Wegovy vs Other GLP-1 Agonists

As checked September 22, 2026, these rows show a verified manufacturer display or the need for an exact quote—not a universal price ranking.

The current Saxenda page reports planned discontinuation and says new savings enrollment ended June 30, 2023, with remaining benefits ending December 31, 2023. Its separate list-price page displays the list-price definition; obtain an exact package quote before relying on a current price. Different active ingredients, labels and package units make a price-only switch unsafe to assume.

10 Strategies to Minimize Wegovy Cost

1. Check the exact formulary entry, authorization criteria, deductible and quantity limit before filling.
2. Ask the pharmacy to quote the prescribed Wegovy presentation and quantity under insurance and cash.
3. Check whether the current Novo commercial offer applies; “as little as $25” is not a universal result.
4. If using self-pay, confirm the package, dose, first-two-fill eligibility and offer expiry.
5. For government coverage, ask the plan which Medicare or Medicaid pathway applies instead of using a commercial card.
6. Compare a branded Wegovy GoodRx result by exact dose, quantity and location.
7. Compare free GoodRx with any Gold membership cost; a membership fee is not a drug discount guarantee.
8. Ask whether a cash purchase affects deductible or out-of-pocket credit before choosing it.
9. Recheck benefits when the plan year or manufacturer terms change; do not carry forward an old offer.
10. Discuss clinically appropriate alternatives with the prescriber rather than switching products solely because a quote is lower.

Exploring Alternatives When Wegovy Costs Are Prohibitive

Zepbound contains tirzepatide and has distinct FDA labels and Lilly savings terms. A different list or cash quote does not establish equivalent coverage or an appropriate switch. Ask the prescriber to match the alternative to the treated condition, current dose, contraindications and plan.

Ozempic's current prescribing information and Wegovy's current prescribing information describe products that both contain semaglutide, but the labels, indications, presentations and coverage decisions differ. Coverage for one product does not prove coverage for the other, and a dose or outcome should not be treated as automatically interchangeable.

Saxenda is a different active ingredient and its manufacturer reports planned discontinuation, so availability matters alongside price. A compounded product raises separate formulation and regulatory questions. Cost comparison is most useful when the product, indication, quantity and source are all specified.

Is Wegovy Sustainable Long-Term? The Cost Question

The original STEP 1 trial studied 1,961 adults without diabetes for 68 weeks of once-weekly semaglutide 2.4 mg or placebo, with structured lifestyle intervention. Both treatment and that structured intervention stopped at week 68. In an exploratory one-year extension, 327 participants across both arms were followed to week 120; the semaglutide arm regained a mean 11.6 percentage points—about two-thirds of its prior loss—after withdrawal. Read the primary extension report for the methods and limits.

This was a selected extension subset, not all 1,961 randomized adults, and later lifestyle participation was not systematically recorded. It describes what happened after treatment and structured support stopped in that study; it is not a universal forecast or a reason to assume lifelong treatment, guaranteed affordability or a fixed discontinuation plan. If cost may change your treatment decision, discuss coverage continuity and alternatives with the prescriber before starting.